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The clinical eﬃcacy of most therapeutic vaccines against cancer has not yet met its promise. Data are emerging that strongly
support the notion that combining immunotherapy with conventional therapies, for example, radiation and chemotherapy may
improve eﬃcacy. In particular combination with chemotherapy may lead to improved clinical eﬃcacy by clearing suppressor cells,
reboot of the immune system, by rendering tumor cells more susceptible to immune mediated killing, or by activation of cells
of the immune system. In addition, a range of tumor antigens have been characterized to allow targeting of proteins coupled to
intrinsic properties of cancer cells. For example, proteins associated with drug resistance can be targeted, and form ideal target
structures for use in combination with chemotherapy for killing of surviving drug resistant cancer cells. Proteins associated with
the malignant phenotype can be targeted to specifically target cancer cells, but proteins targeted by immunotherapy may also
simultaneously target cancer cells as well as suppressive cells in the tumor stroma.
1. Introduction
Traditional cancer treatment modalities include surgery,
radiation therapy, chemotherapy, and for some cancer types,
hormone therapy. Although these treatment modalities are
life extending for many patients, they are rarely curative for
disseminated cancers. The use of cancer vaccines to induce a
therapeutic antitumor immune response in the patient has
huge potential to complement traditional cancer therapies
in a nonoverlapping way. Therapeutic cancer vaccines are
designed to recalibrate the existing host-tumor interaction,
tipping the balance from tumor acceptance towards tumor
control to the benefit of the cancer patient. Additionally,
the highly specific character of the host immune response
minimizes the risk for unattractive adverse events associated
with most other cancer therapies in use today. Such vacci-
nations have been ongoing since early 1990s [1] based on
the long awaited characterization of human tumor antigens
recognized by patient T cells [2]. Encouraged by sporadic
successes, mainly in small phase I trials [3, 4], a high number
of trials have been ongoing worldwide, however so far the
clinical eﬃcacy as demonstrated in large phase III trials
has in most cases be absent or marginal. Recently, however,
the US Food and Drug Administration (FDA) approved an
autologous cellular vaccine (Provenge) for the treatment
of prostate cancer. The approval was based a clinical phase III
trial including 512 patients with asymptomatic or minimally
symptomatic, metastatic prostate cancer and was shown to
increase overall survival (OS) by 4 months compared to
placebo.
Initial attempts to improve vaccination induced biolog-
ical and clinical responses focussed on the use of biological
modifiers or adjuvants with the aim of increasing the
magnitude of the response. To this end, immune stimulatory
molecules such as interleukin-2 (IL-2) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) have been
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used as adjuvants in many animal studies and vaccination
trials. Over the past years it has been realized that the
immune response is in fact comprised not only by responder
cells and molecules, but also cells and molecules responsible
for a counter-response [5, 6]. In turn this has led to
intensified research into the cells and molecules involved
with suppressing immune responses, and ways to inhibit or
delete the counter response [7]. In this regard, it has been
realized that chemotherapy could be used to specifically tar-
get suppressor cells of the immune system [8] or to “reboot”
the immune system for induction of anti-cancer responses
[9]. Moreover, chemotherapy could lead to immunogenic
death of tumor cells [10], depending on the drug, dose, and
administration.
Concerning the characterization of target epitopes rec-
ognized by T cells, the past decades has been characterized
by an increased focus on proteins that functionally link to
the malignant phenotype, for example, to metastasize and
avoid apoptosis [11–16]. Importantly, some of the tumor
associated antigens that comprise antigenic peptides are
functionally related to resistance to conventional therapy,
setting the stage for specifically targeting of cells that escape
conventional therapy [17–21]. Last but not least, the tumor
supportive role of cells in the stroma have encouraged the
characterization of antigens which are expressed not alone
by cancer cells but also or exclusively by cells in the tumor
stroma [21–25].
Therapeutic strategies based on the above findings
are likely to improve the clinical eﬃcacy of therapeu-
tic vaccinations against cancer. Nonetheless, combinations
of chemotherapy—may be even with several drugs in
combination—with immunological strategies, are complex
to evaluate, and demand for careful design of clinical trials
as well as development of new ways to evaluate dose
and schedule combinations rationally [26]. The perspective,
however, is future treatments that combine immunological
treatment with conventional therapy leading to increased
clinical eﬃcacy to the benefit of the patient.
2. Combination with Chemotherapy
Immunological Reboot, and
Immunological Cell Death
Even few years back, the idea of combining chemotherapy
with active immune therapy was unheard of. The dogma
stated that chemotherapy would jeopardize any immune
responses, in part due to the fact that dividing immune
cells are vulnerable to chemotherapeutic drugs, and as
a consequence concurrent active immune therapy with
chemotherapy would be pointless. Nonetheless, the concept
of combining immune therapy with sequential or even
concurrent chemotherapy has lately gained much interest,
for several reasons. First, a number of surprising findings
suggested that combining immuno- and chemotherapy
could lead to better responses in advanced cancer patients
[27]. To this end, data from several studies suggest that
clinical response to chemotherapy is improved if preceded
by immunotherapy [28–31]. A possible explanation for this
phenomenon is that cancer cell death by chemotherapy will
lead to presentation of antigens that may further activate
a treatment-induced T cell response leading to increased
killing of cancer cells by T cells.
Obviously, not only cancer cells are inflicted by systemic
chemotherapy but also cells of the tumor stroma and the
immune system are influenced and as a consequence any
improved reactivity may rely on eﬀects imposed on the
stromal cells, immune system, or on cancer cells—and
probably all may play a role. In general terms, the influence
of chemotherapy may have an impact on normal cells of the
host; for example, cells of the immune system as well as an
impact on cancer cells. These issues are discussed in some
more detail below.
2.1. Chemotherapy in Relation to Normal Cells; Depletion
of Suppressor Cells. Previously, there has been tremendous
focus on the use of molecules or cells that would work
in direction of a more powerful activation of the immune
system in any given immunotherapy, however, the recent
acknowledgement that counter-active cells are at play during
immune responses has led to a focus on suppressor mech-
anisms. There seem to be at least two cell types involved
as key players in cancer, myeloid derived suppressor cells
(MDSC) [6], and regulatory T cells (Treg) [32]. MDSC
are suppressor cells of the innate immune system capable
of inhibiting both innate and adaptive immune responses
[33]. Similarly, regulatory T cells of the adaptive immune
system are capable of suppressing immune responses [5, 34].
Both cell types may be found in high frequencies in cancer
patients—in blood but also at the tumor site, evidence is
now emerging that both cell types are clinically relevant
and predictive for patient survival [6, 35, 36]. Obviously,
these suppressive cells play important roles in controlling
and adjusting immune responses in general and are not in
any way restricted to cancer patients. Hence, the existence
of these populations of suppressive cells underscores the
self-limiting nature of the immune system, characterized by
dual actions, that is, the capacity to kill and destroy upon
antigen recognition as well as the capacity to promote repair
after antigen clearance, removal of dead cells and microbes,
and the subsequent construction of new vessels and down
expression of danger signals. This delicate balance is not
only governed by presence or absence of antigen, but by a
variety of cellular interactions and soluble factors. Thus, any
immune response is composed by active as well as counter-
active cells, and the mechanisms that control the immune
response from initiation to full completion and repair are
poorly understood.
It is now generally accepted that there is a link between
inflammation and cancer—in turn leading to the notion that
a tumor represents a group of cells selected for the capacity to
induce immunological repair instead of clearance. Moreover,
the intimate relation between inflammation and cancer
underscores that the interplay between cells of the immune
system and cancer cells are ongoing from initiation of
oncogenesis and thus that suppressive or repair mechanisms
are an intrinsic phenomenon of cancer [37]. Although data
accumulating over the past few years have revealed much
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new insight into the counter-active cells of the immune
system, we may just have seen the tip of the iceberg. We
recently identified regulatory CD8 T cells present in high
frequencies in cancer patients, and capable of suppressing
cytokine production, proliferation, and cytotoxic activity of
other T cells with a hitherto unheard eﬃcacy [38]. Reaching
frequencies of 0.2% among peripheral blood lymphocytes
(PBL) these CD8 T cells are specific for a single peptide
from the protein heme oxygenase 1 (HO-1). Interestingly,
this protein is expressed by tumor cells as well as during
wound healing [39] and is a key molecule in local immune
suppression [40], thus coupling the action of the novel CD8
T-cell population with the overall function of the protein
recognized. The characterization of these antigen-specific
suppressive CD8 T cells in cancer patients underscores that
there are pros and cons of the immune system in relation
to the interactions between cells of the immune system and
cancer cells.
Thus, Treg, be it CD4 or CD8 cells seem to play a
role for suppression of anticancer immune responses, but
other cells in the tumor stroma as well as cancer cells
themselves may also possess suppressive functions. Normal
cells in the stroma and a fraction of cancer cells may express
indoleamine 2,3-dioxygenase (IDO) [41, 42]. IDO may
suppress T-cell responses directly by tryptophan deprivation
in the microenvironment, and dendritic cells (DCs) may also
express IDO leading to induction of Treg [43]. In turn, Treg
may in fact induce IDO expression in DC further linking the
suppressive network [44]. The drug 1-MT that inhibit IDO
activity is in clinical testing [45], andmay represent a suitable
conditioning or combination partner to immunotherapy.
Interestingly, we recently revealed that IDO is a target for
specific T cells in cancer patients, and that such specific cells
are capable of killing IDO-expressing tumor cells and also
DC provided they express IDO [24]. Thus, the induction of a
response against IDO could diminish the suppressive eﬀect of
IDO and thereby “unleash” a powerful response against the
full spectra of tumor antigens expressed by the cancer cells.
Strikingly, we have used 1-MT added to peptide stimulation
cultures and shown that in some cultures there is a marked
increase in INF-γ secretion measured by EliSpot, suggesting
that PBMC cultures that comprise high frequencies of IDO-
positive cells can be suppressive to T cells—a suppression
that can be unleashed by 1-MT [46].
Steps to clear Treg cells prior to vaccination by a single
administration of chemotherapy, for example, cyclophos-
phamide (CTX) have been attempted and have been shown
to increase induced immune responses in murine [47] as
well as human studies [48, 49]. However, a single clearance
does not appreciate the continuous development of Treg
[50], and other suppressive cells. Continued administration
of low dose CTX was recently shown to be able to selectively
clear Treg and would therefore be far more appealing [8].
However, we recently conducted a clinical vaccination trial
in melanoma patients using the described low dose CTX
without being able to induce Treg clearance or even decrease
in Treg frequency (manuscript in preparation). Also taxanes
which are widely used in the clinic have been studied for
impact on cells of the immune system in particular Treg
[51, 52]. Data from such studies suggest that both paclitaxel
and docetaxel may impair the frequency of Treg either alone
[51] or in combination with carboplatin [53] or CTX [54]. It
could be speculated that the impact of chemotherapy on Treg
depends on the subtype of the regulatory cell. To this end, it
has been shown that induced Treg are rapidly dividing [55],
and such cells could be more vulnerable to chemotherapy.
Concerning manipulations with MDSC this has been
tested in murine models, where Gemcitabine were shown
to selectively eliminate GR1 positive MDSC [56]. Similarly,
it has been found that unresponsive tumor infiltrating
lymphocytes (TIL) of prostate cancer can gain respon-
siveness by blockage of arginase 1 (ARG) known to be
expressed by MDSC [57]. Cyclooxgenase 2 (COX-2) seems
to play a role for induction of MDSC, and administration
of COX-2 inhibitors have been shown to decrease MDSC
development [58, 59]. We are currently running a clinical
trial in melanoma patients in which DC vaccination is
combined with concurrent administration of the COX-
2 inhibitor Celebra (http://www.clinicaltrial.gov/). Whereas
most attempts to manipulate suppressive cells like MDSC
focus on lowering the frequency of the cells, a recent
report demonstrated blockage of the suppressive function of
MDSC by synthetic triterpenoid whereas the frequency of the
cells was unchanged [60]. A potential diﬃculty concerning
selective clearing or blockage of function of MDSC using
chemotherapy is that these cells seem to possess diﬀerent
phenotypes in diﬀerent cancers [6], and have diﬀerent ways
of actions [61, 62] which could be coupled to highly diﬀerent
properties of the cells in response to chemotherapeutic
drugs.
Whether single individual drugs may synergistically
work with, for example, therapeutic vaccination by selective
clearing or decreasing the activity of cells with suppressive
function remains so far elusive, and certainly we are by no
means close to having defined optimal dosage, schedule, and
so forth, for such combinations. Moreover, many cellular
approaches are based on the use of allogeneic tumor cell
lines transfected with vectors encoding immune stimulatory
molecules, which obviously leads to a next level of com-
plexity since the beneficial combination with chemotherapy
may depend on the added stimulatory molecule. To this end,
two recent studies in which allogeneic, GM-CSF-secreting
tumor vaccines were administered to cancer patients in
combination with CTX (and doxorubicin) suggested higher
eﬃcacy in the CTX group [26, 63]. These highly complex
combinations will benefit from designs that are geared to
identify the most clinically relevant combination of the
interacting drugs [26].
2.2. Chemotherapy in Relation to Normal Cells; Conditioning
prior to Adoptive Cell Transfer (ACT). As mentioned, it is
still questionable whether selective clearing of immune cells
with suppressive function is possible using chemotherapy;
however, chemotherapy could also be beneficially used
to “reboot” the immune system prior to initiation of
immune therapy against cancer. For example, the eﬃcacy
of ACT using in vitro expanded TIL in melanoma patients
seems to depend on prior conditioning using chemotherapy
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and/or whole body irradiation therapy [64]. The biological
background for the requirement of conditioning remains
unknown but is probably related to creating space thereby
enabling homeostatic cell division of transferred cells, and
clearing of suppressive cells in the patient [9]. Detailed
insight into the mechanisms that influence the success of TIL
in ACT could potentially open the avenue for development
of an ACT regimen that are associated with fewer and less
serious side eﬀect.
The induction of clinically relevant responses by ACT
using lympho depleting procedures and TIL transfer could
also in part be related to the broad spectra of reactivity
comprised in these TIL cultures. In accordance, we have
studied such TIL cultures from melanoma and head and
neck cancer patients for reactivity against a panel of tumor
antigens using EliSpot and tetramer analyses, and in general
many of these cultures comprise a large number of T-
cell specificities (paper in preparation). T-cell survival and
expansion within the host depends on the availability of
growth-promoting cytokines and regular encounters with
cognate antigen. Under ideal conditions small numbers of
infused T cells can undergo massive expansion in vivo [65].
However, this level of in vivo expansion may not occur
following the adoptive transfer of tumor antigen-specific
T cells owing to the poor immunogenicity of the tumor.
Hence, an alternative approach is to combine adoptive
transfer of T cells with vaccination to facilitate expansion and
maintenance of T cells. The combination of ACT of either in
vitro expanded specific T cells or gene-modified T cells [66]
with vaccination [67] might provide synergism between the
two treatment regimens.
2.3. Chemotherapy in Relation to Normal Cells; Activation
of Cells of the Immune System. Chemotherapy may also
influence cells of the immune system to more potent
activity. To this end, it has been shown that gemcitabine
treatment lead to increased eﬃcacy of immune therapy in
the absence of any direct eﬀect on cancer cells [68]. As
mentioned above CTX may have a role in the clearing of
Treg and is used together with fludarabin as conditioning
prior to ACT. Using CTX alone, it was recently shown
in a murine model that the myelosuppressive action may
lead to subsequent rebound DC generation with increased
capacity to secrete IL-12 [69]. With a more direct action on
DC, vinblastine has been shown to induce DC maturation
[70], and functionally these DCs were superior to untreated
DC in inducing CD8 T-cell responses [71]. Using non-
cytotoxic concentrations, it was recently shown that several
clinically relevant drugs (paclitaxel, doxorubicin, mitomycin
C, and methotrexate) increase antigen presentation in an
autocrine IL-12-dependent manner [72]. Thus, these data
suggest that provided careful examination of the dose and
schedule, it might be possible to harness the dual actions of
chemotherapy to kill some cells and activate others.
2.4. Chemotherapy; Impact on Cancer Cells. Chemother-
apy may also induce an antitumor immune response by
direct influence on the tumor cells. To this end, a panel
of chemotherapeutic agents was screened for inducing
immunological cell death, each drug was studied func-
tionally for the ability of chemotherapy-killed tumor cells
to induce protective immunity upon immunization [73].
The data demonstrated that anthracyclin-treated tumor
cells are particularly eﬀective in eliciting an anticancer
immune response, and further that the mechanism of the
immunogenicity of antracyclin-induced cell death was the
rapid preapoptotic translocation of calreticulin to the cell
surface [73]. This surface exposure of calreticulin endows
cancer cells with an “eat me” signal to dendritic cells, in
turn leading to immunogenic uptake of tumor antigens and
activation of tumor-specific T-cell responses [73]. Thus, to
successfully combine chemotherapy with immune therapy
careful selection of the chemotherapeutic agent is required
since not all agents induce immunological death [74].
Another key denominator of immunogenic cell death
is represented by high-mobility group box 1 (HMGB-
1). Release of HMGB-1 from dying tumor cells leads to
activation of toll-like receptors (TLRs) (2 and 4) and
subsequent immune activation [75]. In this respect, HMGB-
1 localization in the cytosol is associated with autophagy and
cellular escape from apoptosis, in turn conferring resistance
to several therapies including immunotherapy [74]. Also
heat shock proteins (HSPs) which are upregulated upon
specific stress may act as danger signals and be expressed on
the cell surface as “eat me” signals to DC [76]. Interestingly,
it has been shown that treatment of myeloma cells with the
proteasome inhibitor bortezomib leads to surface expression
of HSP90 on the cell surface [77]. A vaccination trial in which
bortezomib is combined with peptide vaccination targeting
the regulators of apoptosis proteins (RAPs) Bcl-2, Mcl-1,
and Bcl-Xl [21] was recently initiated at our institution
(www.clinicaltrial.gov).
Beyond inducing immunogenic tumor cell death,
chemotherapy may render cancer cells more susceptible to
killing by CTL. Thus, 5-fluorouracil (5-FU), CPT-11, or
cisplatin (CDDP) were all shown to increase the sensibility of
the SW480 colon cancer cell line to killing by T cells [78], and
similar data have been found for renal cell carcinoma cells
treated with adriamycin [79]. In both cases the enhanced
lytic sensitivity was at least in part due to upregulation of
costimulatory molecules on cancer cells, for example, LFA-3
and ICAM-1. More recently, Ramakrishnan and colleagues
showed in a murine model that paclitaxel, cisplatin, and
doxorubicin all sensitize tumor cells to more eﬃcient killing
by CTL [80]. In this system, however, the responsible
mechanism on murine as well and human cancer cells
went via upregulation of the mannose-6-phosphate (M6P)
receptor on cancer cells which is required for granzyme B
associated killing [81]. Importantly, CTL established upon
administration of chemotherapy was capable of oﬀ-target
killing of neighboring cells at the tumor site even in the
absence of antigen expression.
The concept of using chemotherapy as an immune
adjuvant is rapidly expanding. Obviously, future testing
in clinical trials will benefit from basic research into the
mechanism(s) of action; how do the cells die and which
pathways are activated for immune activation [82, 83]. This
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will set the stage for initiation of hypothesis driven clinical
trials combining chemotherapy and immune therapy and
form the basis for more rational biological monitoring.
3. Chemotherapy Resistance and
Immune Targeting
Chemotherapeutic agents can induce a series of cellular
responses that impact on tumor cell proliferation and
survival. Perhaps the best studied of these cellular responses
is apoptosis, a physiological cell death program that controls
normal cell numbers during development and disease. A
large number of various drugs in clinical use kill tumor
cells by activation of common apoptotic pathways. Hence,
most cytotoxic anticancer drugs, for example, microtubule
binding drugs, DNA-damaging agents, and nucleosides
induce apoptosis of malignant cells.
Many drugs are capable of inducing clinical response
in the patients with metastatic cancer, however, in most
cases the therapy is not curative due to selection of drug-
resistant cancer cells. A frustrating property of such acquired
resistance of cancer cells is that chemotherapy resistance may
lead to cross-resistance to other drugs with diﬀerent mech-
anisms of action [84]. Drug resistance is a major limiting
factor for the eﬀectiveness of chemotherapy in the treatment
of disseminated cancer [85]. Cancer-associated defects in
apoptosis play a vital role in resistance to chemotherapy and
radiotherapy [86]. An important reason for this impaired
apoptosis is overexpression of RAP [87], that is, the T-cell
antigens survivin and proteins of the Bcl-2 family. Other
mechanisms of drug resistance are exemplified by the tumor
antigen CYP1B1 which may inactivate cytotoxic or cytostatic
drugs thereby influencing the clinical outcome of therapy
[88], and ATP transporters which act by transporting drugs
out of the cell [89].
The mechanisms of drug resistance mentioned above
are associated with expression of proteins that have been
shown to be targets for T cell responses [17–21, 90–95].
Consequently, the combination of immunotherapy targeting
these antigens with conventional chemotherapy appears to
be particularly appealing. In such a setting, conventional
therapy would kill the majority of the cancer cells, leav-
ing only cells that express high levels of target antigens.
Such high-expressers would be particularly vulnerable to
killing by vaccination-induced T cells. Thus, the synergy
of these measures could potentially give a more eﬀective
treatment than the added eﬀect of either regimen alone,
thereby strengthening the already described synergistic eﬀect
of anticancer vaccines and chemotherapy. Furthermore, it
should be noted that chemotherapy only has an eﬀect on
dividing cells, whereas, for example, surviving-specific T cells
in addition are able to kill resting tumor cells.
4. Radiation Therapy in
Combination with Vaccination
Irradiation leads to immunogenic death [73]. Moreover, also
sublethal irradiationmay render cancer cells more vulnerable
to killing by T cells, implying that even surviving irradiated
cancer cells may still facilitate more eﬃcient responses. Total
body irradiation (TBI) is already being used by Dudley
and colleagues as part of a conditioning regimen prior to
ACT [9], indicating additive with more intensified TBI.
Interestingly, a well-known phenomenon related to local
radiation therapy is a bystander eﬀect extending to distant
untreated metastatic sites—an eﬀect potentially mediated
by the immune system [96]. Probably radiation could be
pursued more conceptually in combination with vaccination
as well.
5. Specific or Concurrent Targeting of
Stroma Cells
One of the inherent properties of cancer cells is genetic
instability which in turn allows cancer cells to “escape” dur-
ing therapy. Obviously, the “active-imposing” term “escape”
is in fact a selection process in which cells carrying an
advantageous genetic, epi-genetic, and miRNA signature
are given a survival and/or growth advantage. As already
mentioned, this is a crucial problem concerning chemother-
apy, but also for the success of immune therapy this poses
a problem. In this regard, antigen loss [97] or HLA loss
[98] has been described during immune therapy, and the
background for this lies in the heterogeneity of cancer
cells in turn enabling the presence of cells with escape
properties. Conversely, stroma cells are genetically stable and
possess limited proliferative capacity compared to cancer
cells, implying that the risk of HLA-loss, antigen-loss, or
antigen processing-loss is exceedingly low. Some antigens are
expressed not only by tumor cells but also by cells in tumor
stroma. This applies to survivin, and several other RAP.
Angiogenesis represents an important step in tumor
development [99], and since antiangiogenic therapy targets
the tumor vasculature and prevents tumor growth beyond
micro-metastases, combination of antiangiogenic therapy
and tumor-specific immunotherapy could lead to a syn-
ergistic eﬀect. Active immunotherapy targeting endothelial
products like vascular endothelial growth factor receptor
(VEGFR)-2 protein can delay tumor progression [22], and it
has been shown that vaccination with peptides derived from
VEGFR-1 inhibits tumor growth in mice. This was associated
with suppression of tumor angiogenesis in the absence of
adverse eﬀects [100]. In addition, similar to survivin, Bcl-2
and Mcl-1 are highly expressed in endothelial cells during
tumor angiogenesis [101]. Thus, the targeting of survivin,
Bcl-2, or Mcl-1 in a vaccination setting would beyond
tumor cells also target endothelial cells and thus tumor-
angiogenesis. Indeed this was shown in a mouse model;
vaccination-induced survivin-specific T cells mediated the
eradication of lung tumor metastases and the concurrent
suppression of angiogenesis at the tumor site [102]. The
eﬃcacy of treatment did not inflict on wound healing or
fertility of the mice.
A primary concern of immunizing against angiogenesis-
associated proteins is a potential risk of interference with
normal angiogenesis, especially if the eﬀect is sustained. So
far no vaccination associated toxicity was observed when late
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stage melanoma patients were vaccinated with survivin in a
compassionate use setting despite the fact that strong CTL
responses were introduced in all patients [103]. Nevertheless,
it is clear that even extensive phase I/II trials are not geared
for analyses of potential side eﬀects presenting several years
after termination of the trial, and these issues demand further
attention.
Certainly several targets are available for targeting of
tumor stroma in particular for concurrent targeting of
tumor cells and stroma cells. As already mentioned, IDO are
expressed by fractions of cancer cells in vivo [42], but DCs,
MDSC, and other immune cells in the tumor stroma may
also be IDO positive, and characterized by the same targeting
advantages as, for example, endothelial cells. To this end, it
has been shown that regulatory T cells can be targeted by
immune responses to peptides derived from Foxp3 [25].
6. Multiepitope Strategies and
Additional Immunotherapy
Many current immunological strategies to combat cancer are
already focusing on combining diﬀerent cells and molecules
to increase responses, for example, vaccination combined
with the addition of cytokines or other immune modulating
agents. However, so far most peptide-based vaccination trials
have targeted only a single antigen and with the aim to
increase eﬃcacy an exciting strategy would be to cotarget
biologically connected proteins, for example, RAP, in a
multiepitope setting [104]. A number of diﬀerent RAP have
been described as T-cell antigens in a variety of cancers
[21, 90, 105, 106]. Since coexpression of Bcl-2 family proteins
is a frequent event [87], simultaneous targeting of Bcl-2
proteins may be more eﬃcient than targeting one molecule
alone.
Importantly, drug resistance is casually linked to over
expression of RAP, for example, survivin and Bcl-2 [107,
108]. For combination therapies, vaccination against these
molecules seems to be ideally suited for targeting of chemore-
sistant cancer cells upon conventional therapy, and thereby
possibly prevents relapse of disease [109]. Underscoring this
notion, the coexpression of survivin and Bcl-2 is associated
with poor prognosis in breast cancer [110], implying that
expression of more than one RAP is functionally significant
at least in some indications. To this end, targeting both the
Bcl-2 family proteins and survivin would be particularly
attractive since they act in diﬀerent apoptosis pathways, and
the targeting of both to kill resistant cells upon chemotherapy
would supposedly increase the chances of success. Combined
with adjuvant chemotherapy after primary surgery, adjuvant
vaccination in high risk cancer patients would be suited for a
vaccination that specifically targets not only apoptosis path-
ways but also proteins associated with metastatic behavior,
for example, RhoC [16, 111] or heparanase [15].
7. Conclusions
The immune system has a unique capacity to specifically
recognize and kill cancer cells while leaving normal cells
unharmed. As a consequence, to harness the immune system
in therapeutic vaccinations against cancer is a very promising
approach for the therapy of disseminated cancer. So far,
however, the clinical impact of vaccination has been limited.
Over the past few years, New insight has been achieved
concerning the main suppressive mechanisms that hamper
induction of more powerful immune responses, and also
revealed new knowledge as to how suppressive cells and
molecules could potentially be cleared or inhibited, for
example, in combination with chemotherapy. Similarly, the
immunogenicity of cancer cells has been shown to depend
on the death process induced by the specific drug, thus some
drugs are more prone to act synergistically with vaccination
than others. Added to the above, cancer cells treated with
chemotherapy may be rendered more vulnerable to killing
by T cells, only adding to the potential of improving the
eﬃcacy of vaccination when combined with chemotherapy.
Moreover, antigens may be selected and combined to target
various traits of cancer cells and/or target stroma cells in the
suppressive tumor environment. The available experimental
data should form the basis for initiation of carefully planned
hypothesis driven clinical trials that coupled with stringent
and robust biological and clinical monitoring will be able to
firmly demonstrate the most eﬀective combinations.
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